The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.

Cardiovasc Diabetol · 2019 · PMC6444638 · PMID 30935417

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although it did not reach statistical significance, the decrease of preload-independent stroke work in SHR group was reversed by 12-week treatment of empagliflozin.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.